The applicants have discovered a method of treating malignancies which comprises administering effective amounts of 5-fluorouracil, interferon-.alpha. and a compound formula (I): ##STR1## wherein R is selected is selected from the group consisting of alkyl of 1 to 5 carbon atoms, alkene of 2 to 5 carbon atoms and alkynyl of 2 to 5 carbon atoms; R.sub.1 is 2'-deoxyribofuranosyl.

Direct fluorination of uracil, cytosine and their derivatives, in the presence of a non-aqueous solvent, by fluorine gas to produce 5-fluorouracil, 5-fluorocytosine, 5-fluorouracil derivatives and 5-fluorocytosine derivatives is disclosed. The non-aqueous solvent is an acid or alcohol, which can be partly or fully fluorinated or chlorinated, of up to 8 carbon atoms, such as trifluoroacetic acid. Novel compounds produced by the reaction, such as 5,5-difluoro-5,6-dihydro-6-(2,2,2-trifluoroethoxy) ...

An improved method for synthesizing 1-(tetrahydro - 2-furanyl) - 5-fluorouracil from a silyl derivitive of 5-fluorouracil (bis - trimethylsilyl 5-fluorouracil) by reacting the same with 2-chlorotetrahydrofuran. The reaction is carried out at controlled conditions of temperature and under an inert gas. Yields in excess of 80% of the theoretical are obtained as calculated upon the starting amounts of 5-fluorouracil.

The present invention is directed to the use of pharmaceutical compositions containing anti-retroviral effective amounts of (a) d4T and (b) 5-fluorouracil or a prodrug, or salt thereof.

A composition for delivering 5-fluorouracil to cancer tissues, of a cancer sensitive to 5-fluorouracil, in warm blooded animals, comprising effective amounts of 1-(n-hexylcarbamoyl)-5-fluorouracil and uracil in a molar ratio of 1:0.1-10, respectively.

5-Fluorouracil derivatives represented by general; formula I: ##STR1## wherein R represents an acyl group derived from an unsaturated higher fatty acid selected from the group consisting of triene higher acids, pentaene higher acids, and hexaene higher fatty acids, can be used as for inhibiting platelet aggregation and an anticancer chemotherapeutic agent. They may be mixed with a pharmaceutically acceptable carrier or a diluent to form a medicinal preparation.

An anti-cancer composition comprising a 5-fluorouracil and uracil.

5-Fluorouracil derivative having the formula ##STR1## wherein R represents hydrogen atom or 2-tetrahydrofuryl group is produced by reacting more than equi-mole of 2,3-dihydrofuran with 5-fluorouracil in a polar aprotic solvent with a catalytically effective amount of a catalyst selected from the group consisting of metal halides, non-metal halides, tertiary amine salt of inorganic acids and organic acids in neutral or basic condition at 50.degree. to 150.degree. C under pressure.

A facile process for the production of Ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] which comprises reacting 2,4-bis-trimethylsilyl uracil with 2-chlorotetrahydrofuran to produce 1-tetrahydro-2-furanyluracil at low temperatures in a dry non-aqueous solvent, e.g. a halogenated hydrocarbon solvent such as methylene chloride. Subsequently the desired final product is produced by direct fluorination of the uracil ring as the last step utilizing a fluorinating agent such as trifluoromethylhypof...

A 1-(N-substituted carbamoyl)-5-fluorouracil derivative represented by the following general formula: ##STR1## R is a 4-alkoxycyclohexyl group-containing radical which is 2,3,4-trimethoxycyclohexcylethyl, 2,3,4-trimethoxycyclohexyl, 2,4-dimethoxycyclohexylmethyl, 3,4-dimethoxycyclohexylethyl, 2,4-dimethoxycyclohexyl, 2,4,5-trimethoxycyclohexyl, 3,4-dimethoxycyclohexylmethyl, 3,4,5-trimethoxycyclohexyl, 4-ethoxycyclohexyl or 4-ethoxycyclohexylmethyl. The compounds are carcinostatic agents. The co...